secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2023-07-13T23:59:59+00:00
Accession:  0001549595-23-000039
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix Q2 net loss narrows to $24.3M ($0.45/sh) on $30.7M revenue; Gilead pays $20M for IRAK4 license
--------------------------------------------------------------------------------

- Net loss of $24.3M ($0.45 EPS) vs $45.4M ($1.01 EPS) in prior year; revenue $30.7M vs $11.4M.
- Cash and marketable securities $308.6M as of May 31, 2023, down from $325.6M on Feb 28, 2023.
- Gilead exercised option on NX-0479 (IRAK4 degrader) for $20M; up to $425M in milestones + royalties.
- Phase 1b expansion started for NX-2127 in DLBCL and MCL; Phase 1a data for NX-5948 expected H2 2023.
- NX-2127 and NX-5948 preclinical data showed potent activity against BTKi resistance mutations at AACR and ICML.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959523000039/0001549595-23-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959523000039/nrix-20230713.htm
  HTML page:      https://secwatch.observer/filing/0001549595-23-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer